Kintara Therapeutics, Inc.
12707 High Bluff Drive, Suite 200
San Diego, CA 92130
November 2, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
| Re: | Kintara Therapeutics, Inc. (the “Company”) |
Registration Statement on Form S-3 (File No. 333-249675)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on November 4, 2020, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
November 2, 2020
Page 2
|
| Very truly yours,
KINTARA THERAPEUTICS, INC. | |
|
|
|
|
|
| By: | /s/ Scott Praill |
|
| Name: | Scott Praill |
|
| Title: | Chief Financial Officer |
-2-
